Selected Publications

Rivella S, Callegari JA, May C, Tan CW, Sadelain M. The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites, J Virol. 2000;74:4679-4687.

Gambhir SS, Herschman HR, Cherry SR, Barrio JR, Satyamurthy N, Toyokuni T, Phelps MD, Larson SM, Balatoni J, Finn R, Sadelain M, Tjuvajev J, Blasberg R. Imaging transgene expression with radionuclide imaging technologies. Neoplasia. 2000;2:118-138.

Sadelain M. A “friendly merger” in the war on cancer. Mol Ther. 2000;1:115-116.

Latouche JB, Sadelain M. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat Biotechnol. 2000;18:405-409.

Schnell S, Young JW, Houghton AN, Sadelain M. Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells. J Immunol. 2000;164:1243-1250.

Rivière I, Gallardo HF, Hagani A, Sadelain M. Retroviral-mediated gene transfer in murine and human primary T-lymphocytes. Mol Biotechnol J. 2000;15:133-142.

Gong MC, Latouche JB, Krause A, Heston WD, Bander NH, Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate specific membrane antigen. Neoplasia. 1999;1:123-127.

Jacobs A, Dubrovin M, Hewett J, Sena-Estevers M, Tan CW, Slack M, Sadelain M, Breakefield XO, Tjuvaev J. Functional coexpression of HSV-1 thymadine kinase and green flourescent protein: implications for imaging of transgene expression. Neoplasia. 1999;1:154-161.

Sadelain M, Blasberg RG. Imaging transgene expression for gene therapy. J Clin Pharmacol. 1999;8:34S-39S.

Tjuvajev J, Joshi A, Callegari J, Lindsley L, Joshi R, Balatoni J, Finn R, Larson SM, Sadelain M, Blasberg RG. A general approach to the non-invasive imaging of transgenes using cis-linked herpes simplex virus thymidine kinase. Neoplasia. 1999;1:315-320.

Hagani AB, Rivière I, Tan C, Krause A, Sadelain M. Activation conditions determine susceptibility of murine primary T-lymphocytes to retroviral infections. J Gene Med. 1999;1:341-351.

Rivière I, Sadelain M. Genetic treatment of severe hemoglobinopathies. Hematologie. 1999;5:512-522.

Sadelain M, May C, Rivella S, Glade Bender J. Basic principles of gene transfer in hematopoietic stem cells. Prog Exp Tum Res. 1999;36:1-19.

Rivella S, Sadelain M. Genetic treatment of severe hemoglobinopathies: the combat against transgene variegation and transgene silencing. Semin Hematol. 1998;35:112-125.

Rivière I, Sunshine MJ, Littman DR. Regulation of IL-4 expression by activation of individual alleles. Immunity. 1998;9:217-228.

Krause A, Guo HF, Latouche JB, Tan C, Cheung NKV, Sadelain M. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med. 1998;188:619-626.

Kaptein LC, Van Beusechem VW, Rivière I, Mulligan RC, Valerio D. Long-term in vivo expression of the MFG-ADA retroviral vector in rhesus monkeys transplanted with transduced bone marrow cells. Hum Gene Ther. 1997;8:1605-1610.

Rivière I, Sadelain MWJ. Methods for the construction of retroviral vectors and the generation of high titer producers. In: Robbins P, ed. Methods in Molecular Medicine, Gene Therapy Protocols. Totowa, NJ: The Humana Press Inc; 1997:59-78.

H. Hacein-Bey, Cavazzana-Calvo M, Le Deist F, Dautry-Varsat A, Hivroz C, Rivière I, Danos O, Heard JM, Sugamura K, Fischer A, De Saint Basile G. gamma-c gene transfer into SCID X1 patients' B-cell lines restores normal high-affinity interleukin-2 receptor expression and function. Blood. 1996;87:3108-3116.